摘要
目的 检测肿瘤特异性共享抗原NY ESO 1/LAGE 1基因在肝癌中的表达情况及其诱导肝癌患者体液免疫应答的能力 ,为利用NY ESO 1/LAGE 1为抗原进行肝癌的疫苗免疫治疗提供依据。方法 利用逆转录 聚合酶链反应 (RT PCR)方法检测了 34例肝癌患者癌和癌旁组织NY ESO 1/LAGE 1基因mRNA水平的表达 ;利用酶联免疫吸附实验检测了NY ESO 1/LAGE 1在 37例肝癌患者中诱导自身抗体产生的能力。结果 34例肝癌组织中 9例 ( 2 6 .5 % )表达NY ESO 1,12例 ( 35 3% )表达LAGE 1。其中 ,同一标本中共表达NY ESO 1/LAGE 1的病例数为 7例 ;表达其中至少一种基因的14例 ,占总数的 4 1.2 %。所检测的 37份肝癌患者血清中 ,6例患者血清抗NY ESO 1抗体阳性 ,5例为Ⅲ期及以上患者 ,1例为Ⅱ期患者。结论 NY ESO 1/LAGE 1在肝癌患者中表达率较高 ,并可诱导自身体液免疫应答 。
Objective To investigate the potential of utilizing NY-ESO-1/LAGE-1 antigens in hepatocellular carcinoma (HCC) vaccines. Methods RT-PCR method was used to detect the expression of NY-ESO-1/LAGE-1 mRNA in the cancerous tissues and adjacent tissues resected from 34 patients with HCC. ELISA assay was adopted to analyze the NY-ESO-1 specific antibodies in 37 serum samples of HCC patients, 1 positive control sample, and 8 samples of normal persons. Results Nine (26 5%) out of the 34 HCC samples were NY-ESO-1 mRNA positive, while 12 (35 3%) were LAGE-1 positive. Among them, seven HCC samples expressed both genes, and 14 (41 6%) expressed at least one of the genes. Among the 37 serum samples tested six contained high titer of anti-NY-ESO-1 antibodies. Five of the samples were from stage Ⅲ or later stage HCC patients; one was from a stage Ⅱ patient. Conclusion NY-ESO-1 /LAGE-1 mRNA is expressed in a high frequency in HCC tissue samples, and induces autologous humoral responses in HCC patients. Both of the antigens can be considered as candidates for HCC vaccines.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2004年第23期1980-1982,共3页
National Medical Journal of China
基金
美国癌症研究所基金资助项目(DesignedGrant)
北京市科技新星基金资助项目(H0 2 0 83 2 13 70 13 0 )
北京大学"2 11"工程免疫学科基金资助项目
